These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2571292)

  • 1. Rilmenidine: a novel antihypertensive agent.
    Safar ME
    Am J Med; 1989 Sep; 87(3C):24S-29S. PubMed ID: 2571292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the pharmacology of rilmenidine.
    Montastruc JL; Macquin-Mavier I; Tran MA; Damase-Michel C; Koenig-Berard E; Valet P
    Am J Med; 1989 Sep; 87(3C):14S-17S. PubMed ID: 2571291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I1 receptors, cardiovascular function, and metabolism.
    Bousquet P
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):317S-321S. PubMed ID: 11721890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. I1 imidazoline receptors in cardiovascular regulation: the place of rilmenidine.
    Head GA; Burke SL
    Am J Hypertens; 2000 Jun; 13(6 Pt 2):89S-98S. PubMed ID: 10921527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of imidazoline-preferring receptors in regulation of sympathetic tone.
    Sannajust F; Head GA
    Am J Cardiol; 1994 Dec; 74(13):7A-19A. PubMed ID: 7998588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents.
    Head GA
    Ann N Y Acad Sci; 1999 Jun; 881():279-86. PubMed ID: 10415926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents.
    Head GA
    Ann N Y Acad Sci; 1995 Jul; 763():531-40. PubMed ID: 7677371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does rilmenidine act in vivo on central alpha 2-adrenoceptors modulating noradrenaline release?
    Suaud-Chagny MF; Mermet C; Tibiriça E; Bousquet P; Gonon F
    Eur J Pharmacol; 1992 Mar; 213(2):305-7. PubMed ID: 1355739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilmenidine and vigilance. Review of clinical studies.
    Mahieux F
    Am J Med; 1989 Sep; 87(3C):67S-72S. PubMed ID: 2571296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current data on the pharmacology of rilmenidine].
    Montastruc JL; Macquin-Mavier I; Damase-Michel C; Dard B; Tran MA; Valet P
    Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():25-9. PubMed ID: 2517006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of the alpha 2-adrenoceptor agonist rilmenidine.
    Van Zwieten PA
    Am J Cardiol; 1988 Feb; 61(7):6D-14D. PubMed ID: 2894160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of imidazoline receptors and alpha2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine.
    Chan CK; Burke SL; Head GA
    J Hypertens; 2007 Jan; 25(1):147-55. PubMed ID: 17143186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity of rilmenidine for I1-imidazoline-binding sites in rabbit proximal tubule cells.
    Gargalidis-Moudanos C; Parini A
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S59-62. PubMed ID: 8642808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
    Reid JL; Panfilov V; MacPhee G; Elliott HL
    Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
    van Zwieten PA
    Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of central noradrenergic and serotonergic pathways in the cardiovascular actions of rilmenidine and clonidine.
    Head GA; Burke S
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):819-26. PubMed ID: 1725893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on rilmenidine: clinical benefits.
    Reid JL
    Am J Hypertens; 2001 Nov; 14(11 Pt 2):322S-324S. PubMed ID: 11721891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors.
    Tibiriça E; Feldman J; Mermet C; Monassier L; Gonon F; Bousquet P
    Eur J Pharmacol; 1991 Dec; 209(3):213-21. PubMed ID: 1686768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.
    Yu A; Frishman WH
    J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.